Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.82 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.61 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002100 | 1.00 | EGFR (0.82) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL1105295 | 1.00 | EGFR (0.82) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL5001859 | 0.93 | EGFR (0.81) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL1105317 | 0.93 | EGFR (0.81) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL5001861 | 0.93 | EGFR (0.81) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL5524423 | 0.91 | EGFR (0.80) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL1105240 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL12694678 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL1095818 | 0.90 | EGFR (0.81) | EGFRERBB2 | |
| SCHEMBL1095820 | 0.90 | EGFR (0.81) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8278446-B2 | reacting 4-amino-6-chloro-pyrimidine-5-carbaldehyde with 4-benzyloxy-3-chloro-phenylamine in an aqueous solvent and a catalytic amount of hydrochloric acid, to providw 4-amino-6-(4-benzyloxy-3-chloro-phenylamino)-pyrimidine-5-carbaldehyde, then oximination with (2-morpholin-4-yl-ethyl)-hydroxylamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | MAP3K2, MAP3K1, MAP3K20 | EGFR 1201/4885ERBB2 124/4885ERBB4 410/4885 |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | DHPS, DPYD, DCPS | EGFR 1036/4885ERBB2 301/4885ERBB4 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.